Adaptive Biotechnologies Q1 Loss Narrows

May 01, 2025 — 05:34 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company, Thursday reported first-quarter net loss of $29.8 million or $0.20 per share, compared to $47.5 million or $0.33 per share for the same period in 2024.

Revenue was $52.4 million for the quarter, representing a 25% increase from $41.9 million in the first quarter in the prior year.

MRD revenue was $43.7 million for the quarter, representing a 34% increase from the first quarter in the prior year. Immune Medicine revenue was $8.7 million for the quarter, representing a 6% decrease from the first quarter in the prior year.

Adaptive Biotechnologies expects full year revenue for the MRD business to be between $180 million and $190 million, updated from the previous range between $175 million and $185 million. No revenue guidance is provided for the Immune Medicine business.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Adaptive Biotechnologies Q1 Loss Narrows

Tags

Latest Articles